Summary of Senti Biosciences Conference Call Company Overview - **Company**: Senti Biosciences - **Focus**: Development of logic gating and gene circuits for cell therapy, particularly in oncology [3][4] Core Industry Insights - **Oncology Drug Development Challenge**: The primary challenge is to kill cancer cells without harming healthy cells. Traditional therapies often struggle to find clean targets that minimize side effects [3][4] - **Logic Gates Concept**: Senti is innovating by using logic gates to enhance the specificity of cell therapies, allowing for the recognition and killing of cancer cells while protecting healthy cells [4][5] Key Product: SENTI-202 - **Target Indication**: Acute Myeloid Leukemia (AML) is identified as a significant area of unmet need due to the difficulty in finding clean targets for treatment [8][9] - **Mechanism**: SENTI-202 utilizes two CAR receptors: an activating CAR for cancer targets (CD33 and FLT3) and an inhibitory CAR to protect healthy hematopoietic stem cells via the VSIG2 target [9][10] - **Clinical Data**: - Phase 1 study showed a 42% complete response (CR) rate in relapsed refractory AML patients, with 100% of CR patients being minimal residual disease (MRD) negative and a median durability of 7.6 months [24][26] - Safety profile was consistent with NK cell therapies, primarily grade 1 or 2 events [24][34] Competitive Landscape - **Unmet Need in AML**: The median survival for relapsed refractory AML patients is approximately 5.3 months, with existing therapies showing low CR rates (12-20%) [26][27] - **Senti's Differentiation**: Senti's approach with validated targets (CD33 and FLT3) and the use of engineered NK cells is positioned as a potential best-in-class solution compared to existing NK therapies that have shown lower response rates [82][83] Regulatory and Development Plans - **RMAT Designation**: Senti has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, facilitating closer collaboration for clinical development [42] - **Next Steps**: Plans to initiate pivotal trials later this year, with a focus on expanding indications beyond AML to high-risk myelodysplastic syndromes (MDS) [65][66] Future Directions - **Solid Tumor Applications**: Senti is exploring the application of its technology in solid tumors and other modalities, indicating a broad potential for its logic gating technology [69][70] - **Investigator Interest**: There is significant interest from major AML centers to participate in upcoming trials, reflecting the high demand for effective treatments in this space [61][62] Additional Considerations - **Patient Population**: The trial is designed to include a broad range of patients, with a focus on those who can tolerate low-dose chemotherapy [49][51] - **Biomarker Selection**: Currently, patients must be CD33 positive to participate, but ongoing analyses will continue to refine this requirement [52][54] This summary encapsulates the key points discussed during the conference call, highlighting Senti Biosciences' innovative approach to addressing significant challenges in oncology, particularly in AML treatment.

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1] - The company will present its Gene Circuit technology, pipeline progress, and strategic priorities at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases by leveraging a synthetic biology platform to engineer Gene Circuits [3] - The Gene Circuits are designed to specifically target and kill cancer cells while sparing healthy cells, increasing specificity to target tissues, and allowing for control even after administration [3] - The company's pipeline includes cell therapies engineered with Gene Circuits aimed at addressing challenging liquid and solid tumor indications, with preclinical evidence supporting their efficacy in both NK and T cells [3] - Senti Bio is also exploring the potential applications of Gene Circuits in other modalities and diseases beyond oncology through ongoing partnerships [3]

Senti Biosciences Conference Call Summary Company Overview - **Company**: Senti Biosciences (NasdaqCM:SNTI) - **Focus**: Development of gene circuit-based therapies for cancer treatment, specifically targeting acute myeloid leukemia (AML) with Senti 202 Key Industry Insights - **Industry**: Oncology, specifically the treatment of relapsed refractory AML - **Current Treatment Landscape**: - Existing therapies yield low complete remission (CR) rates of 12%-25% and CR/CRh rates of 20%-35% [16][17] - Median overall survival for relapsed refractory AML patients is approximately five months [16] Core Points from the Call - **Senti 202 Overview**: - A first-in-class off-the-shelf logic-gated CAR-NK cell therapy targeting CD33 and FLT3 [8] - Achieved a 50% overall response rate and a 42% CR/CRh rate in a phase 1 trial with 20 heavily pretreated relapsed refractory AML patients [8][39] - 100% of complete remission patients were MRD negative, indicating significant clinical benefits [9][40] - **Mechanism of Action**: - Utilizes a logic-gated approach to selectively kill cancer cells while sparing healthy cells [6][7] - Incorporates an OR gate to recognize cancer targets and a NOT gate to protect healthy cells [6][11] - **Clinical Trial Results**: - Phase 1 trial demonstrated durable responses with a median duration of composite CR of 7.6 months [9][39] - High MRD negative rates correlate with better long-term outcomes [9][40] - Safety profile supports outpatient dosing, with most adverse events being low-grade and manageable [21][39] - **Regulatory Designations**: - Received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation, facilitating closer collaboration with the FDA [9][40] - **Market Potential**: - Addressable market for Senti 202 includes approximately 28,000 relapsed refractory AML patients in the U.S. and EU, with potential expansion into newly diagnosed AML and pediatric AML populations [13][14] Additional Important Insights - **Patient Population**: - The trial enrolled patients with multiple adverse risk characteristics, with a median age of 49 years and a history of multiple prior therapies [26][27] - Senti 202 is not restricted by mutation status, allowing it to benefit a broader range of patients [21] - **Future Directions**: - Plans to initiate pivotal studies in 2026, with ongoing discussions with the FDA regarding trial design [41][43] - Potential for expanding indications to include solid tumors and other hematological malignancies [45] - **Technology Platform**: - Senti's broader gene circuits platform includes various types of genetic circuits that enhance the efficacy and safety of cell and gene therapies [44][45] Conclusion - Senti 202 shows promising efficacy and safety in treating relapsed refractory AML, with a strong potential for market impact and future expansion into other indications. The innovative logic-gated approach may address significant unmet needs in oncology, particularly for patients with limited treatment options.

Core Viewpoint - Senti Biosciences, Inc. is set to present updated clinical results for its SENTI-202 therapy at the ASH Annual Meeting on December 9, 2025, highlighting its innovative approach in treating hematologic malignancies [1][2]. Group 1: Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies for patients with incurable diseases, utilizing its proprietary Gene Circuit platform [4]. - The company aims to engineer Gene Circuits that can precisely target and kill cancer cells while sparing healthy cells, enhancing specificity and control in treatment [4]. Group 2: Product Details - SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) [3]. - The therapy includes an OR GATE for activating CAR that targets CD33 and/or FLT3, a NOT GATE to protect healthy cells, and calibrated-release IL-15 to enhance cell persistence and activity [3]. - Currently, Senti Bio is enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202, which could be a first-in-class allogeneic treatment for AML/MDS patients [3]. Group 3: Conference Call Details - The conference call discussing the clinical results will be hosted by key executives including Timothy Lu, MD, PhD, and Kanya Rajangam, MD, PhD, along with a hematologist from the Sarah Cannon Research Institute [2]. - Interested participants can access the call via a domestic or international phone line, and the webcast will be available on the company's website for 90 days post-event [2].